Merck & Co. (MRK)

Quick facts

Marketed products

• Keytruda · Oncology · revenue 29500
  Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response.
• Winrevair · Cardiovascular · revenue 1443
  Winrevair works by binding to and inhibiting the activity of activin receptors, which play a role in the development of pulmonary arterial hypertension.
• Prevymis · Infectious Disease · revenue 978
  Prevymis works by inhibiting the DNA terminase complex of the cytomegalovirus, preventing the virus from replicating.
• Elspar · Oncology · revenue 600
  RYLAZE kills leukemic cells by depleting plasma asparagine, which they need for survival.
• Welireg · Oncology · revenue 509
  Belzutifan inhibits HIF-2α, blocking its interaction with HIF-1β to reduce expression of genes linked to tumor growth.
• Bavencio · Oncology · revenue 400
  Bavencio blocks the PD-L1 protein, allowing the immune system to recognize and attack cancer cells.
• Tindal · Other
• Fosamax · Bone
  Fosamax works by inhibiting bone resorption, allowing bone density to increase.
• Aminohippurate · Hematology
• Andion · Hematology
  Andion works by inhibiting Vitamin K-dependent gamma-carboxylase, an enzyme necessary for blood clotting.
• Emend · Oncology
  Emend works by blocking the action of a natural substance called substance P, which is involved in the vomiting reflex.
• KEYTRUDA QLEX · Other
• Diprolene · Oncology
  Diprolene works by binding to the glucocorticoid receptor in the skin, which reduces inflammation and suppresses the immune system.
• Celestone Soluspan · Immunology
• Zinplava · Infectious Disease
  Zinplava works by binding to and neutralizing toxins produced by Clostridium difficile bacteria.
• Victrelis · Infectious Disease
• Cancidas · Infectious Disease
  Cancidas works by inhibiting the synthesis of beta-1,6-glucan, a critical component of the fungal cell wall.
• Cetrotide · Other
• Ovidrel · Immunology
• Primaxin · Metabolic
  Primaxin works by inhibiting the action of dehydropeptidase, an enzyme that breaks down certain antibiotics, thereby protecting them from degradation and allowing them to reach effective concentrations in the body.
• Org 36286 · Other
• Immune Support · Immunology
• DAPTACEL™ · Immunology
• Ortho-Cept · Other
• Sincortex · Other
• Decadron-La · Oncology
• Dexamethasone Sodium Phosphate · Immunology
• Drixoral · Infectious Disease
• Biphemanil · Other
• Pifeltro · Immunology
  Pifeltro works by blocking the reverse transcriptase enzyme, which is essential for the replication of the HIV virus.
• Trusopt · Cardiovascular
  Trusopt works by inhibiting the enzyme carbonic anhydrase 2, which is involved in the production of aqueous humor in the eye.
• DTP-IPV · Other
• Zepatier · Oncology
  Zepatier works by blocking the NS5A protein of the hepatitis C virus, preventing it from replicating.
• Vasotec · Cardiovascular
  ACE inhibitor prodrug that is converted to enalaprilat, blocking angiotensin-converting enzyme to lower blood pressure.
• Integrilin · Metabolic
  Integrilin blocks the binding of fibrinogen to platelets, preventing them from clumping together and forming clots.
• Invanz · Metabolic
  Invanz works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.
• Steglatro · Metabolic
  Steglatro works by blocking the kidneys' ability to reabsorb glucose, allowing excess glucose to be excreted in the urine.
• Ortho-Novum 10/11-21 · Bone
• Zetia · Metabolic
  Zetia works by blocking the absorption of cholesterol in the small intestine.
• Propecia · Urology
  Selective type II 5-alpha-reductase inhibitor that blocks conversion of testosterone to dihydrotestosterone (DHT), treating BPH and male pattern hair loss.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Merck & Co. portfolio CI brief
• Merck & Co. pipeline updates RSS